Oncternal Therapeutics Inc (ONCT)
US68236P2065 - Common Stock
Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT) (the “Company”) today announced updated data from its Phase 1/2...
Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT) (the “Company”) today announced its decision to discontinue its...
ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q2 2024
ONCT stock results show that Oncternal Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Oncternal Therapeutics (NASDAQ:ONCT) just reported results for the second quart...
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
No dose-limiting toxicities or concerning side effects in our Phase 1/2 study with ONCT-534, our dual-action androgen receptor inhibitor (DAARI), for...
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...
Oncternal Therapeutics to Present in JonesTrading Healthcare Summit
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...
Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...
ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q1 2024
ONCT stock results show that Oncternal Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Oncternal Therapeutics (NASDAQ:ONCT) just reported results for the first quarte...
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
Fourth dosing cohort at 300 mg per day is fully enrolled for the Phase 1/2 study with ONCT-534, our dual-action androgen receptor inhibitor (DAARI), for...
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...
ONCT Stock Earnings: Oncternal Therapeutics Misses EPS, Beats Revenue for Q4 2023
ONCT stock results show that Oncternal Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
ONCT Stock Earnings: Oncternal Therapeutics Misses EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Oncternal Therapeutics (NASDAQ:ONCT) just reported results for the fourth quart...
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
Third dosing cohort fully enrolled for our Phase 1/2 study for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with...
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...
Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...
Oncternal Therapeutics announces a reverse stock split (NASDAQ:ONCT)
Oncternal Therapeutics announced a reverse stock split to comply with Nasdaq's minimum bid price requirement.
Oncternal Therapeutics Announces Reverse Stock Split
SAN DIEGO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...